LIAPHEN™ Fibrinogen

Intended Use

LIAPHEN™ Fibrinogen kit is an immuno-turbidimetric assay for in vitro quantitative determination of Fibrinogen antigen (Fib:Ag) on human citrated plasma or in purified medium using a manual or automated method. Reagents are in the liquid presentation, ready to use.

Summary and Explanation

Technical Fibrinogen is a 340 Kd soluble plasma glycoprotein, synthesized in the liver, containing 6 peptidic chains, with a 2 to 2 symmetry, and linked by disulfide bridges (2 Aα, 2 Bβ and 2 γ chains). Thrombin clots fibrinogen and forms fibrin, which is then stabilized by activated Factor XIII in presence of calcium. Fibrinogen is lysed by plasmin to fragments X and Y, first, then D and E.

Clinical Fibrinogen concentration in normal human plasma is usually in the range 2 to 4 g/L. Elevated fibrinogen concentrations (> 4g/L) are observed in clinical situations associated with inflammation and have also been considered as a risk factor for cardiovascular disease and thrombosis. Hypofibrinogenemia is mainly associated with severe liver disease, or excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen have been described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.

Principle

LIAPHEN™ Fibrinogen is an immunoturbidimetric method, based on antigen-antibody reaction: fibrinogen antigen of the sample reacts with polyclonal rabbit anti-human fibrinogen antibodies, leading to latex particles agglutination. This agglutination can be directly detected by a change of absorbance. The absorbance change is directly proportional to the amount of fibrinogen in the sample.

Reagents

R Latex, liquid form. Contains BSA and small amounts of sodium azide (0.9 g/L)
4 vials of 5 mL.